Tritonpoint Wealth LLC Has $1.18 Million Stock Position in Zoetis Inc. $ZTS

Tritonpoint Wealth LLC lessened its position in shares of Zoetis Inc. (NYSE:ZTS) by 53.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,382 shares of the company’s stock after selling 10,771 shares during the quarter. Tritonpoint Wealth LLC’s holdings in Zoetis were worth $1,180,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its position in Zoetis by 1.0% in the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock worth $6,190,326,000 after purchasing an additional 419,777 shares during the period. Nordea Investment Management AB increased its holdings in Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after buying an additional 2,179,578 shares during the period. Brown Advisory Inc. increased its holdings in Zoetis by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after buying an additional 250,829 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after buying an additional 550,859 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Zoetis by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock worth $620,595,000 after acquiring an additional 496,320 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 0.1%

Shares of Zoetis stock opened at $117.83 on Friday. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The stock has a market capitalization of $49.74 billion, a P/E ratio of 19.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.98. The company has a 50-day simple moving average of $122.71 and a 200 day simple moving average of $128.22. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s dividend payout ratio is 35.22%.

Analyst Ratings Changes

ZTS has been the topic of several recent research reports. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. UBS Group set a $136.00 price target on shares of Zoetis in a research note on Thursday, January 29th. The Goldman Sachs Group raised Zoetis to a “buy” rating in a report on Monday, December 15th. HSBC set a $140.00 price objective on Zoetis in a research note on Wednesday, December 10th. Finally, BTIG Research restated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Zoetis presently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.